Abstract
After completion of growth hormone (GH) treatment, 19 patients with isolated “idiopathic” growth hormone deficiency (IGHD) and 15 with post-irradiation growth hormone deficiency (PRGHD) were asked to undergo retesting of GH secretion with an insulin tolerance test and/or an arginine stimulation test. PRGHD patients are those with CNS tumours distant from the hypothalamic-pituitary axis (n=13) or acute lymphatic leukaemia (n=2), who had received cranial or cranospinal irradiation.
All 15 patients with PRGHD remained GH deficient [peak GH level <7mU/l (n=10) and 7-15mU/l (n=5)]. However of the 19 retested IGHD patients, 5 (26%) had peak GH responses >15mU/l (regarded now as transient or false F-IGD) and were indistinguishable from the remainder [permanent or true T-IGHD, peak GH levels <7mU/l (n=12) and 7-15 mU/1 (n=2)] by pre-treatment anthropometry and post-treatment height SDS, but had a lower first year height velocity (Mean Velocity 5.4cm/yr ±0.9 for F-IGHD v 8.7cm/year ±1.75 for T-IGHD p<0.01) and height acceleration on treatment (Mean acceleration 2.1cm/yr ±1.7 for F-IGHD v 5.2cm/yr ±2.3 for T-IGHD p<0.05). By current practices 2 F-IGHD patients may have been distinguished by sex-steroid priming.
Thus post-irradiation GH deficiency appears to be permanent but errors of diagnosis in IGHD are common.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clayton, P., Price, D. & Shalet, S. GROWTH HORMONE SECRETION ON COMPLETION OF TREATMENT IN ISOLATED “IDIOPATHIC” AND POST-IRRADIATION GROWTH HORMONE DEFICIENCY. Pediatr Res 20, 1181 (1986). https://doi.org/10.1203/00006450-198611000-00048
Issue Date:
DOI: https://doi.org/10.1203/00006450-198611000-00048